Boehringer Ingelheim is pursuing leading science to deliver novel cancer cell-directed therapies, innovative immuno-oncology strategies, and smart combination approaches that can transform the lives of patients.

Gain an overview of our oncology pipeline, which includes cancer cell-directed compounds, immuno-oncology compounds and compounds targeting both cancer cells and immune cells.

Find a suitable clinical trial for your patient with this list of our ongoing studies in oncology.